INITIATION OF LIPID-LOWERING THERAPY AS PRIMARY PREVENTION OF
CARDIOVASCULAR DISEASE IN THE ELDERLY
Abstract
Aim: This study aimed to analyse the initiation adherence phase to
lipid-lowering therapy for primary prevention of cardiovascular disease
in a Spanish population aged 70 years or older. The secondary objective
was to identify the determinants of initiation and early
discontinuation. Methods: Observational study conducted in the CARhES
(CArdiovascular Risk factors for HEalth Service research) cohort. People
aged 70 and older with a first prescription of a lipid-lowering drug and
without a previous Major Adverse Cardiovascular Event were selected
(2018-2021). Data on sociodemographics, clinical conditions, drugs and
use of health services were collected from clinical and administrative
electronic databases. The study population was classified into:
non-initiation, early discontinuation (i.e., discontinuation after the
first dispensing) and initiation with more than one dispensing. Their
characteristics were compared. Determinants of initiation and early
discontinuation were explored. Results: Among the 15,019 people studied,
80.2% initiated the medication, 11.2% showed an early discontinuation
and 8.6% were non-initiators. An older age or conditions such as
dementia, diabetes or depression reduced the likelihood of initiation,
while obesity and a high pharmacological burden increased it. People
over 90 of age or those prescribed a statin in combination were more
likely to have an early discontinuation. Conclusion: Non-initiation and
early discontinuation are common among older people prescribed
lipid-lowering drugs as primary prevention of cardiovascular disease by
the first time. The presence of chronic pathologies other than
cardiovascular ones should be considered when assessing whether or not
to prescribe these drugs in the elderly.